Adipose-derived stromal/stem cells and extracellular vesicles for cancer therapy

Expert Opin Biol Ther. 2022 Jan;22(1):67-78. doi: 10.1080/14712598.2021.1954156. Epub 2021 Jul 21.

Abstract

Introduction: Mesenchymal stromal/stem cells (MSCs) hold great perspective for the therapy of a host of diseases due to regenerative and anti-inflammatory properties by differentiation into diverse cell populations, homing to damaged tissue regions, paracrine effects, and release of extracellular vesicles.

Areas covered: This review describes the isolation, characterization, and potential use of MSCs and ADSCs for benign and malignant diseases. The MSCs may be administered as whole cells or in form of their secretome that is held responsible for most of their beneficial effects. A special constituent of the paracrine components are the extracellular vesicles (EVs) that carry a biologically potent cargo of proteins, cytokines, and RNA.

Expert opinion: The applications of MSCs and ADSCs are amply documented and have been investigated in preclinical models and many unregulated and a few controlled trials. Larger numbers of MSCs and ADSCs can be obtained for allogeneic transfer but imply difficulties including perseverance of the cells in vivo and possible differentiation into harmful cell types. MSC-derived cell-free preparations are easier to handle and manufacture for various applications. Especially, with the help of bioreactors, EVs can be obtained in excessive numbers and preloaded or charged with proteins, cytokines, and regulatory RNA specimen to treat inflammatory diseases and cancer.

Keywords: Mesenchymal stromal/stem cells; adipose-derived stromal/stem cells; bioreactor; drug carrier; extracellular vesicles; therapy.

Publication types

  • Review

MeSH terms

  • Adipose Tissue / metabolism
  • Cell Differentiation
  • Cytokines / metabolism
  • Extracellular Vesicles* / metabolism
  • Humans
  • Mesenchymal Stem Cells*
  • Neoplasms* / metabolism
  • Neoplasms* / therapy

Substances

  • Cytokines